Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime. (1st April 2020)

• Record Type: Journal Article
• Authors: Shields, Ryan K; Iovleva, Alina; Kline, Ellen G; Kawai, Akito; McElheny, Christi L; Doi, Yohei
• Is Part Of: Clinical infectious diseases. Volume 71:Number 10(2020)
• Page Start: 2713
• Page End: 2716
• Publication Date: 2020-04-01
• Subjects: R2 loop -- deletion -- β-lactamase -- cefepime; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa355
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: We report 2 independent patients from whom carbapenem and ceftazidime-avibactam–resistant Enterobacter cloacae complex strains were identified. The ceftazidime-avibactam resistance was attributed to a 2–amino acid deletion in the R2 loop of AmpC β-lactamase, which concurrently caused resistance to cefepime and reduced susceptibility to cefiderocol, a novel siderophore cephalosporin.